Nutra Pharma has been issued a patent by the U.S. Patent and Trademark Office that protects their therapy for Multiple Sclerosis (MS). The patent is entitled, “Modified anticholinergic neurotoxins as modulators of the autoimmune reaction.”

October 19, 2011 — Coral Springs, Florida — Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV/AIDS), Adrenomyeloneuropathy (AMN) and Pain, announced today that its wholly-owned subsidiary, ReceptoPharm, has received approval from the United States Patent and Trademark Office (USPTO) for its patent describing the composition of matter and the use of neurotoxins for the treatment of Multiple Sclerosis (MS). Click here to read on.

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Nutra Pharma Receives Patent for Their Multiple Sclerosis Drug", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

A new research study reported in the Journal of Pain shows that acute and chronic lower back pain have distinct components. Thanks to these findings, doctors may become better able to predict which cases of acute pain will turn into chronic pain (2011;12:792-800). [Pain Medicine News, September 2011, volume 9:09]

Acute pain is defined as severe pain, typically due to an injury, that lasts a relatively short time. Chronic pain is pain that lasts a long time. In the case of lower back pain, chronic back pain is defined as back pain lasting longer than twelve weeks.

For the purpose of this study, three categories of back pain were recognized: acute pain, defined as lasting under six weeks, subacute pain, defined as lasting seven to twelve weeks, and chronic pain that had lasted three months or longer. The subjects included 40 people with acute back pain and 37 with chronic back pain.

Researchers from the Rehabilitation Institute of Chicago and Northwestern University’s Feinberg School had the subjects rate their back pain and complete multiple questionnaires. The subjects answered questions designed to assess the intensity of their pain, their use of medications and the presence or absence of depression. The overall purpose of the study was to look at differences in pain characteristics between subacute and chronic lower back pain and to assess the relationship of these characteristics to the pain’s intensity.

Perhaps unsurprisingly, the pain intensity was rated significantly higher by most subjects with chronic back pain than by those in the subacute category. Surprisingly, there was only a slightly greater occurrence of depression in chronic pain patients versus those with subacute pain. The main difference between the two groups was where on the lower back the subjects tended to feel pain. Patients with subacute pain were more likely to feel pain on one side of the body, radiating from one particular spot. Those with chronic pain mainly felt it on both sides of the body.

The researchers concluded that if a patient with subacute lower back pain feels the pain on both sides of the body, it is more likely to turn into chronic pain than if the pain is only felt on one side. Previously, very little had been known about the different characteristics of acute, subacute and chronic lower back pain. The study’s findings give physicians a new tool for predicting patients’ likelihood of developing chronic lower back pain.

For lower back pain sufferers in any category, how to treat the pain is the question. In many cases, the cause of back pain cannot be pinpointed. Even when it can, treatment is often elusive. Surgery may correct some problems that lead to back pain. In some cases, physical therapy is helpful. Some gentle forms of exercise, such as yoga, tai chi or water aerobics, may be adapted for patients with back problems and help ease the pain.

However, patients with acute or chronic back pain often find it necessary to take pain relieving medications. Many effective drugs, both prescription and over the counter, exist. Most of them fall into one of two categories: opiate-based drugs or non-steroidal anti-inflammatory drugs (NSAIDs).

Both categories of medication can be risky. Patients taking opiate-based painkillers can easily become addicted to them. Even for those who do not develop addiction, these medications can have serious, sometimes life threatening, side effects. Harmful physical effects are more likely for people who must take the medication in the long term, which is typically true of patients with chronic back pain.

NSAIDs are non-addictive and do not necessarily carry the same side effects as opiate-based painkillers. However, even NSAIDs can pose serious health risks when taken in excess. People suffering from serious and chronic pain may find that they need more than the recommended dose to get effective relief, which can easily lead to excessive use of the drugs.

A third alternative, Nyloxin™, is available in spray or gel form. Originally developed in India from cobra venom, Nyloxin™ has been clinically proven effective against pain at many levels. On a one to ten scale, with one being relatively minor pain and ten being very severe, Nyloxin™ effectively relieves pain in the two to six range. A stronger version of the drug, aptly named Extra Strength Nyloxin™, relieves pain above the six level.

Despite its venomous origins, Nyloxin™ has every indication of being safer than both opiate-based pain relievers and NSAIDs. It is not addictive and does not carry the same risks of side effects. It is sold over the counter, lessening patients’ need for prescription pain relievers. Even as medicine struggles to come up with an objective system for rating levels of pain, Nyloxin™ provides safe and effective pain relief at all levels.

---

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Study Shows Unique Characteristics of Acute vs. Chronic Low Back Pain", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Nutra Pharma announced today that DNAA, Inc will serve as their Distributor in Panama for its Nyloxin-branded pain relievers.

Coral Springs, FL. – October 14, 2011 – Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain announced today that it has selected DNAA, Inc. to serve as the exclusive distributor in Panama for its Nyloxin-branded pain relievers. Please click here to read the rest of the story.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions are intended to identify “forward-looking statements.” Actual results could differ materially from those projected in Nutra Pharma’s (“the Company”) business plan. The distribution of Nyloxin™ into Panama through DNAA, Inc. should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. Additionally, this distribution agreement does not ensure that the Company will have material sales in Jordan. The Company’s filings may be accessed at the SEC’s Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

# # #

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Nutra Pharma Announces Distributor in Panama for Their Nyloxin Pain Relievers", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

On September 27, 2011, the Arthritis and Rheumatism Journal published the findings of a study on arthritis, conducted by Duke University’s Medical Center and supported with grants from the National Institutes of Health and the Arthritis Foundation.

It has long been known that excess weight on joints contributes to the pain of osteoarthritis. But in this new 20-week study, scientists at Duke University discovered that exercise alone improves arthritis symptoms – even in obese mice that consume high-fat diets and maintain unhealthy weights. During the study two sets of male mice were used; 10 mice were fed a regular healthy diet (13.5% in fat), while the other 10 were fed a diet high in fat (60% in fat). The mice on high fat diets experienced rapid weight gain (55% increase in body mass), a decrease in the ability to process glucose and an increase in chronic inflammation, such as that which is common in osteoarthritis.

But although the obese mice continued to eat a high-fat diet and maintain their excessive weight, they ran regularly on their exercise wheels for weeks, causing many of the negative effects of the diet to decrease. Among those noted were improvements in glucose tolerance levels as well as a decrease in inflammation. “Even though there was the same amount of body fat, the fat was different,” explained Timothy M. Griffin, PhD from Oklahoma Medical Research Foundation (formerly from Duke). “I don’t want to say exercise is turning off that inflammatory signal, it just impairs it.”

Experiments regarding the findings of this study are now being conducted on humans.

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " New Study Shows Physical Activity Improves Symptoms of Arthritis in Obese Lab Mice", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Risk of Atrial Fibrillation Associated with NSAID and (COX) 2 Inhibitor Use

The British Journal of Medicine recently published the findings of a population-based study, regarding the risk of atrial fibrillation related to the use of non-steroidal, anti-inflammatory drugs (NSAIDs) and (Cox) 2 inhibitors.

The study was conducted in Denmark using 32,602 patients, who received initial diagnoses of atrial fibrillation upon inpatient or outpatient hospital care. It was determined that the use of NSAIDs increased the occurrence of atrial fibrillation and atrial flutter by approximately 40%, and the use of (COX) 2 inhibitors increased the occurrence by approximately 70%. The findings showed that increases were most notable among new users of these two types of drugs.

Read details of the study and results here.

 

Regular Use of Non-Aspirin NSAIDs Linked to Increase in Kidney Cancer

Two recent findings from a lengthy Nurses’ Health Study (that began in 1990) and a Health Professionals Follow-Up Study (that began in 1986) suggest that long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) increase the incidence of renal cell carcinoma.

Usage of analgesics was monitored every two years during these studies, following 77,525 women and 49,403 men. 333 renal cell carcinoma cases were documented during the study. It was determined that aspirin and acetaminophen  did not increase the incidence of renal cancer in the subjects studied, but the use of non-aspirin, non-steroidal anti-inflammatory drugs increased the incidence by 51%.

Read an abstract of the study here.

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " In the News: Analgesics Under Scrutiny for Health Risks", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.